

	2nd Name	Article 1 (1)	HCPs: City of Principal Practice (HCPs: City where registered)	Article 2	Country of principal practice	Article 3	Principal Practice Address	Article 3	Unique country identifier	OPTIONAL	Article 3	Deviations and Details to HCPs	Article 3 (1) 4	Contributions (Number of Events (HCPs: 2021-12-31 & 2022-12-31))	Pay for services and consultancy (HCPs: 2021-12-31 & 2022-12-31)	Non-activity		
														Sponsorship agreements with HCPs (1) and parties approved by HCPs in exchange for Cash	Aggregation Fees (1) and/or unpaid (2)	Tax and Accommodation (1) Fees	Related Expenses agreed in the fee for services or consultancy contracts including travel & accommodation expenses in the past year	
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP in a full column of values during a year for an individual HCP will be summed or aggregated should be available for the individual Recipient or public authorities' requirements only, an agreement																	
	Reporting: Doctor													0.00	0.00-0.00	1.000-2.000	0.00	1.000-2.000
														0.00	0.00-0.00	0.00	0.00	0.00-0.00
	OTHER (NOT FULLY DISCLOSED) - where consultation cannot be disclosed (for an individual Recipient, for legal reasons)																	
	Aggregate amount attributable to transfers of value to main Recipients - Art. 3 (2)													0.00	0.00-0.00	0.00	0.00	0.00-0.00
	Number of Recipients in aggregate disclosure - Art. 3 (2)													0.00	0.00-0.00	0.00	0.00	0.00-0.00
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3 (2)													0.00	0.00-0.00	0.00	0.00	0.00-0.00
HCPs	No Data Available																	
	OTHER (NOT FULLY DISCLOSED) - where consultation cannot be disclosed (for an individual Recipient, for legal reasons)																	
	Aggregate amount attributable to transfers of value to main Recipients - Art. 3 (2)													0.00	0.00-0.00	0.00	0.00	0.00-0.00
	Number of Recipients in aggregate disclosure - Art. 3 (2)													0.00	0.00-0.00	0.00	0.00	0.00-0.00
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3 (2)													0.00	0.00-0.00	0.00	0.00	0.00-0.00
R&D	AGGREGATE DISCLOSURE																	
	Transfers of Value in Research & Development as defined - Article 3 (2) and Schedule 1																	
EPHA Member Associations Association Pharmaceutique Luxembourgpoise (APL) http://www.apl-pharm.com/ Luxembourg 1 2011																		